IN BRIEF: Merck trial shows Koselugo effective in treating adults

Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and ...

Alliance News 12 November, 2024 | 7:50PM
Email Form Facebook Twitter LinkedIn RSS

Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase 3 Komet trial shows statistically significant and clinically meaningful improvement in objective response rate in adult neurofibromatosis patients treated with AstraZeneca and Merck's joint-developed medication Koselugo. The condition is a rare progressive genetic disease in which tumours develop on nerve sheaths and may lead to disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment and bladder or bowel dysfunction. Koselugo is approved to treat children with the disease but there is little intervention available for adults.

"Adults with NF1 are in critical need of treatment options to help manage symptomatic, inoperable plexiform neurofibromas. These positive results from the Phase 3 Komet trial demonstrate the potential to expand the use of Koselugo beyond pediatric patients to also treat adult patients living with this rare and challenging genetic condition," says Scot Ebbinghaus, vice president, global clinical development, Merck Research Laboratories.

Merck current share price: USD99.44

12-month change: down 3.0%

AstraZeneca current share price 9,860.79 pence

12-month change: down 3.8%

By Aidan Lane, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 9,990.00 GBX 0.05
Merck & Co Inc 98.58 USD -2.13

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures